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Abstract
Background
Chikungunya virus (CHIKV) is a globally re-emerging arbovirus for which previous studies
have indicated the majority of infections result in symptomatic febrile illness. We sought to
characterize the proportion of subclinical and symptomatic CHIKV infections in a prospec-
tive cohort study in a country with known CHIKV circulation.
Methods/Findings
A prospective longitudinal cohort of subjects6 months old underwent community-based
active surveillance for acute febrile illness in Cebu City, Philippines from 2012-13. Subjects
with fever history were clinically evaluated at acute, 2, 5, and 8 day visits, and at a 3-week
convalescent visit. Blood was collected at the acute and 3-week convalescent visits. Symp-
tomatic CHIKV infections were identified by positive CHIKV PCR in acute blood samples
and/or CHIKV IgM/IgG ELISA seroconversion in paired acute/convalescent samples. En-
rollment and 12-month blood samples underwent plaque reduction neutralization test
(PRNT) using CHIKV attenuated strain 181/clone25. Subclinical CHIKV infections were
identified by8-fold rise from a baseline enrollment PRNT titer <10 without symptomatic in-
fection detected during the intervening surveillance period. Selected CHIKV PCR-positive
samples underwent viral isolation and envelope protein-1 gene sequencing. Of 853 sub-
jects who completed all study procedures at 12 months, 19 symptomatic infections (2.19
per 100 person-years) and 87 subclinical infections (10.03 per 100 person-years) occurred.
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The ratio of subclinical-to-symptomatic infections was 4.6:1 varying with age from 2:1 in 6
month-5 year olds to 12:1 in those >50 years old. Baseline CHIKV PRNT titer10 was as-
sociated with 100% (95%CI: 46.1, 100.0) protection from symptomatic CHIKV infection.
Phylogenetic analysis demonstrated Asian genotype closely related to strains from Asia
and the Caribbean.
Conclusions
Subclinical infections accounted for a majority of total CHIKV infections. A positive baseline
CHIKV PRNT titer was associated with protection from symptomatic CHIKV infection.
These findings have implications for assessing disease burden, understanding virus trans-
mission, and supporting vaccine development.
Author Summary
Chikungunya virus (CHIKV) is a re-emerging mosquito-borne pathogen for which the
majority of infections have been considered to result in febrile illness. We sought to char-
acterize the proportion of subclinical and symptomatic CHIKV infections in a prospective
cohort of subjects6 months old who underwent active surveillance for acute febrile ill-
ness from 2012–13 in Cebu City, Philippines. Symptomatic CHIKV infections were de-
tected by PCR and/or ELISA in acute/convalescent blood samples. Subclinical infections
were identified by neutralizing antibody seroconversion between enrollment and 12-
month visits without symptomatic infection. Among 853 subjects who completed all study
activities at 12 months, 19 symptomatic and 87 subclinical infections occurred (2.19 and
10.03 per 100 person-years, respectively). A positive baseline CHIKV PRNT titer was asso-
ciated with 100% (95%CI: 46.1, 100.0) protection from symptomatic infection. Phyloge-
netic analysis showed Asian genotype closely related to strains from the recent Caribbean
epidemic. These findings can help to assess disease burden, understand virus transmission,
and support vaccine development.
Introduction
Chikungunya virus (CHIKV) is a re-emerging mosquito-borne pathogen that has rapidly ex-
panded its geographic reach over the past decade in Africa, Asia, the Indian and Pacific Ocean
regions, and Europe. In December 2013, the first case of autochthonous CHIKV infection was
confirmed in the Americas on the Caribbean island of Saint Martin and quickly spread to other
Caribbean islands and parts of Central/South America [1,2]. The continental United States
confirmed its first locally acquired case in Florida in July 2014 [3]. Given the large number of
travelers to currently affected areas and the widespread distribution of appropriate Aedesmos-
quito vectors, spread to other parts of the Americas and Europe is likely [2,4].
CHIKV is a 12kb single-stranded, positive-sense RNA virus in the genus Alphavirus and
family Togaviridae. CHIKV was first isolated from a patient in Tanzania during a febrile illness
outbreak in 1952–53 [5,6]. The primary vectors in large human outbreaks are Aedes aegypti
and Aedes albopictus with humans serving as the amplifying host in urban settings. Three
CHIKV genotypes are known to circulate: West African, East/Central/South African (ECSA),
and Asian. In 2005, CHIKV re-emerged in widespread epidemics in the Indian Ocean region
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and subsequently in Asia, perhaps aided by an A226V mutation in the envelope protein-1 (E1)
gene of the ECSA genotype allowing the virus to spread more efficiently in Ae. albopictus [7].
In the current Caribbean epidemic, the circulating CHIKV has been identified as Asian geno-
type closely related to strains from China (2012), the Philippines (2012), and Micronesia/Yap
(2013) [8]. Although Ae. aegypti is thought to be the main vector in the Caribbean outbreak,
both Ae. aegypti and Ae. albopictus populations from different regions of the Americas may be
able to transmit all three CHIKV genotypes [9].
The classic clinical presentation of chikungunya consists of febrile illness with symmetric
polyarthralgia in the extremities [10]. In a minority of patients, arthralgias/arthritis can persist
for months or even years. Severe or atypical disease is more likely in neonates, older adults and
those with chronic medical conditions. Previous studies have demonstrated that a majority of
infections present with acute fever accompanied by other overt symptoms. However, assump-
tions about the clinical presentation of CHIKV infection have largely been based on sentinel
surveillance or cross-sectional serosurveys [11,12,13,14].
At present, no licensed chikungunya vaccine exists although several are in development
[15,16]. Efficacy trials of vaccine candidates have been hampered by the unpredictability of chi-
kungunya incidence in the field [15,17]. Development efforts would be enhanced by a better
understanding of infection risk in endemic areas and the establishment of immune correlates
of risk and protection.
Here, we present results from a prospective longitudinal seroepidemiological cohort study
of acute febrile illness conducted in Cebu City, Philippines from 2012–13. Chikungunya was
first reported in the Philippines in the 1950’s with sporadic but infrequent outbreaks occurring
over the next several decades [18,19,20]. Since 2011, an increasing number of chikungunya out-
breaks have been reported to the Philippine Department of Health (DOH) [20]. However, no
prospective longitudinal community-based cohort study has detected a meaningful number of
confirmed CHIKV infections. In this first year of a two-year study, we sought to characterize
the proportion of subclinical and symptomatic CHIKV infections. We were able to identify
>12 total CHIKV infections per 100 person-years of surveillance and classify these as subclini-
cal or symptomatic.
Methods
Ethics Statement
The study was approved by the Institutional Review Boards of Vicente Sotto Memorial Medical
Center (Philippine DOH) in Cebu City, Philippines, and the Walter Reed Army Institute of Re-
search. Written informed consent was obtained from subjects18 years old and from parents
of subjects<18 years old. Written assent was obtained from children12 years old.
Study Location and Population
The study was conducted in Cebu City, Philippines, an urban center of>800,000 residents lo-
cated within the central Visayas region, one of three major island groups in the Philippines. All
subjects were enrolled from the community of Punta Princesa, a dense urban area of 0.96 sq
km with approximately 27,000 residents (Philippine National Statistics Office, 2010).
Prospective Longitudinal Cohort
A prospective longitudinal community-based seroepidemiological cohort study of acute febrile
illness was initiated in 2012 in Cebu City primarily to evaluate the incidence of influenza and
dengue virus infections and secondarily to evaluate the incidence of other causes of acute
Chikungunya in a Philippine Cohort
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febrile illness. FromMarch-May 2012, subjects6 months of age were recruited by door-to-
door canvassing within the community. Approximately 200 subjects were targeted for enroll-
ment in each of five age groups: 6 months-5 years, 6–15 years, 16–30 years, 31–50 years, and
>50 years old. Since this was an exploratory study, the target size of the cohort was largely
based on logistical considerations. Only one subject per household was enrolled. At enrollment,
demographic and health questionnaires were administered and baseline blood samples collect-
ed. Subjects were instructed to report any fevers during the study period, and were monitored
for acute febrile illnesses by weekly telephone calls or home visits. Any fever history within the
prior seven days triggered an acute illness visit by study nurses who performed a clinical assess-
ment that included a standardized symptoms questionnaire and acute blood collection. All
acute blood samples were collected within seven days of illness onset. Follow-up visits to assess
clinical status were conducted at 2, 5 and 8 days after the acute visit. Nasal and throat swabs
were also collected at the acute, 2, 5 and 8 day visits but are not part of the current analysis. At
3 weeks, a convalescent visit was performed that included a clinical assessment and conva-
lescent blood collection. Twelve months after enrollment (approximately March-June 2013),
routine follow-up visits were conducted that included blood collections. All blood samples
were processed into serum aliquots on the day of collection and stored at -70°C. These banked
sera were available for further chikungunya testing. Acute serum samples were tested by re-
verse transcriptase polymerase chain reaction (RT-PCR) to detect CHIKV RNA [21,22]. Paired
acute and 3-week convalescent serum samples were tested by an in-house CHIKV IgM/IgG en-
zyme-linked immunosorbent assay (ELISA) [23]. Paired enrollment and 12-month serum
samples were tested by CHIKV plaque reduction neutralization test (PRNT) [23].
Laboratory Assays
CHIKV RT-PCR. Viral RNA was extracted from 140 ul of subject serum using viral RNA
extraction kit (Qiagen, Valencia, CA, USA). A two-step nested PCR was modified from Porter
et al. and Laras et al. to amplify the capsid region of CHIKV [21,22].
CHIKV IgM/IgG ELISA. An in-house quantitative anti-CHIKV capture IgM/IgG ELISA
was modified from Innis et al. and performed as previously described [24,25]. Subject serum at
1:100 dilution, anti-CHIKV K42 monoclonal antibody (provided by Dr. Alan Schmaljohn, U.S.
Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA) diluted at
1:1000, and sucrose acetone-extracted CHIKV antigen (50 HA units) were utilized in the assay.
CHIKV ELISA IgM40 units was considered positive.
CHIKV PRNT. PRNT was performed using the procedure of Russell et al. with modifica-
tions as previously described [23,26]. Four-fold serial dilutions of subject serum starting at 1:10
were incubated with attenuated strain 181/clone25 derived from a CHIKV Asian strain isolated
from Thailand in 1962 [27]. Virus-serum admixtures were incubated on a monolayer of
Macaca mulatta kidney (LLC-MK2) cells in a 12-well plate with 30–50 plaques in control wells.
PRNT data was expressed as the reciprocal of the serum dilution causing 80% plaque reduction
as extrapolated by probit regression.
CHIKV sequencing. Three CHIKV-positive acute blood samples were selected for E1
gene sequencing based on relatively strong CHIKV RT-PCR signal. Two additional CHIKV-
positive acute blood samples were selected from different months of the year for viral isolation
in Ae. albopictus-derived C6/36 cells as previously described [28], followed by sequencing of
the isolate. DNA fragments of E1 gene were amplified using AccessQuick RT-PCR System
(Promega, Madison, WI, USA) and purified using PCR purification kits (Qiagen, Valencia,
CA, USA). Sanger sequencing of E1 gene was performed by AITbiotech (Singapore).
Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA) was used to generate
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consensus sequences. E1 gene sequences of 1,320 bps (nucleotide position 999–11,313 of proto-
type CHIKV S27 gene sequence) were aligned with other CHIKV E1 sequences from GenBank
to construct a phylogenetic tree using MEGA 6 software and neighbor-joining (maximum
composite likelihood) methods with 1,000 replicates for bootstrap testing.
Study Definitions
Acute symptomatic CHIKV infection was defined as a febrile illness with positive CHIKV PCR
in the acute sample, or positive CHIKV IgM ELISA in the acute and/or convalescent samples
with rising IgM levels, or4-fold rise in CHIKV IgG ELISA in the paired acute/convalescent
samples. Subclinical CHIKV infection was defined as8-fold rise in the 12-month PRNT titer
from a baseline enrollment titer of<10 with no acute symptomatic CHIKV infection detected
during the intervening surveillance period. An enrollment PRNT titer10 was considered to
indicate past CHIKV infection.
Statistical Analysis
Descriptive statistics for infection rates, symptoms and other characteristics were performed.
Associations among categorical variables were estimated and tested for significance using chi-
square or Fisher’s exact test as appropriate. P-value<0.05 was considered significant. Exact
odds ratio (OR) and confidence interval (CI) for baseline PRNT status were calculated using
conditional maximum likelihood estimates. Percent protection attributable to PRNT status
was calculated as 100(1-OR). All analyses were performed using R version 3.0.2 (R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
A total of 1007 subjects with approximately equal gender distribution were enrolled in the co-
hort with about 200 subjects contained in each of the five age groups (Table 1). Two hundred
seventy (270) acute febrile illnesses were detected with 267 (98.9%) acute and 261 (96.7%) con-
valescent blood samples collected among 223 subjects. Twenty (7.5%) of 267 acute samples
were CHIKV PCR-positive from 20 different individuals, of which all were also positive by
ELISA. All subjects with ELISA seroconversion between acute and convalescent samples were
also PCR-positive in the acute sample. Of the initial 1007 enrolled subjects, 853 completed all
study activities per-protocol including enrollment and 12-month blood collections. Among
these 853 per-protocol subjects, 19 symptomatic CHIKV infections occurred during 867 per-
son-years of surveillance. An additional 87 subclinical CHIKV infections occurred in these
per-protocol subjects based on8-fold rise in 12-month PRNT titer from a baseline enroll-
ment titer of<10 (Fig 1) [Note: PRNT values using 50% plaque reduction in addition to 80%
were also calculated for all PRNT results. Two subjects meeting the definition of “subclinical
infection” by PRNT80 values but with baseline enrollment PRNT50 titer of10 were not in-
cluded among the 87 subclinical infections due to the possibility of prior CHIKV infection.].
The 12-month PRNT titers ranged from 229 to 2,030 in symptomatic infections and from 64
to 3,347 in subclinical infections (Fig 2). The incidence of symptomatic CHIKV infection per-
protocol, therefore, was 2.19 per 100 person-years (95%CI: 1.36, 3.35), and of subclinical infec-
tion per-protocol was 10.03 per 100 person-years (95%CI: 8.09, 12.31). Sequencing of the E1
gene from five PCR-positive samples/isolates revealed all five to be Asian genotype (GenBank
accession numbers KM014692 to KM014696), closely related to strains from New Caledonia
(2011), China (2012), Micronesia/Yap (2013), Saint Martin (2013) and British Virgin Islands
(2014) (Fig 3).
Chikungunya in a Philippine Cohort
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The incidence of symptomatic CHIKV infection in different age groups ranged from 0.55
(>50 years old) to 4.23 (6–15 years old) per 100 person-years (see Table 2 for rates in each age
group with confidence intervals). The incidence of subclinical CHIKV infection ranged from
6.46 (6 months-5 years old) to 12.68 (6–15 years old) per 100 person-years (Table 2). The ratio
of subclinical-to-symptomatic infections ranged from 2:1 (6 months-5 years old) to 12:1 (>50
years old). Seroprevalence at enrollment of positive CHIKV PRNT titer (i.e.,10) increased
with each older age group although the degree of increase with each age group varied (Table 2).
Among just those subjects with negative CHIKV PRNT at enrollment, the incidence of symp-
tomatic CHIKV infection ranged from 1.41 (>50 years old) to 4.27 (6–15 years old) per 100
person-years; subclinical CHIKV infection ranged from 6.51 (6 months-5 years old) to 26.7
(31–50 years old) per 100 person-years; total CHIKV infection ranged from 9.77 (6 months-5
years old) to 30.51 (31–50 years old) per 100 person-years (see Table 3 for rates in each age
group with confidence intervals). The ratio of subclinical-to-symptomatic infections was the
same as in all per-protocol subjects since all CHIKV infections occurred in subjects with nega-
tive baseline PRNT titer.
Clinical features of all 20 symptomatic CHIKV infections (of which 19 occurred in per-pro-
tocol subjects) are shown in Table 4. Only two (10%) subjects sought medical care; one was
hospitalized. Arthralgia was present in nine (45%) cases: 3/14 (21%) subjects15 years old
and 6/6 (100%) subjects>15 years old. At the 3-week convalescent visit, symptoms had
Table 1. Description of cohort subjects.
Characteristic n (%)
Enrolled subjects 1007 (100)
Per-protocol subjects* 853 (84.7)
Age: Enrolled subjects / Per-protocol subjects
6 mos—5 yrs 203 (20.2)/ 148 (17.4)
6–15 yrs 201 (20.0) / 184 (21.6)
16–30 yrs 200 (19.9) / 168 (19.7)
31–50 yrs 202 (20.1) / 170 (19.9)
>50 yrs 201 (20.0) / 183 (21.5)
All ages 1007 (100) / 853 (100)
Male gender at enrollment 501 (49.8)
Number in household at enrollment
1 16 (1.6)
2–3 206 (20.5)
4–6 528 (52.4)
7–10 235 (23.3)
>10 22 (2.2)
Number of children in household at enrollment
0 179 (17.8)
1 224 (22.2)
2 228 (22.6)
3 183 (18.2)
>3 193 (19.2)
*Subjects who completed all study activities at 12 months including enrollment and 12-month
blood collections.
n = number.
doi:10.1371/journal.pntd.0003764.t001
Chikungunya in a Philippine Cohort
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003764 May 7, 2015 6 / 14
completely resolved in 18 (90%) subjects. The remaining two subjects had rhinorrhea/nasal
congestion and/or cough at 3 weeks.
The relationship between occurrence of symptomatic CHIKV infection and baseline enroll-
ment CHIKV PRNT titer is shown in Table 5. PRNT data was available only in per-protocol
Fig 2. Dot plot of chikungunya virus (CHIKV) plaque reduction neutralization test (PRNT) titers at
enrollment and 12 months in per-protocol subjects. All 19 symptomatic and 87 subclinical CHIKV
infections had enrollment PRNT titer <10 and 12-month titers ranging from 229 to 2,030 in symptomatic
infections and 64 to 3,347 in subclinical infections; 239 subjects had positive titers at enrollment ranging from
10 to 1,785; and 505 subjects had negative titers at both enrollment and 12 months.
doi:10.1371/journal.pntd.0003764.g002
Fig 1. Study flow chart.
doi:10.1371/journal.pntd.0003764.g001
Chikungunya in a Philippine Cohort
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003764 May 7, 2015 7 / 14
subjects. Among the 853 per-protocol subjects, all 19 symptomatic CHIKV infections occurred
in subjects with baseline PRNT titer<10 (Table 5). A positive baseline CHIKV PRNT titer
(i.e.,10) was associated with 100% (95%CI: 46.1, 100.0) protection from symptomatic
CHIKV infection. A positive baseline PRNT titer was present in 239 per-protocol subjects with
titers ranging from 10 to 1,785 (Fig 2).
Discussion
The incidence of CHIKV infection in our study conducted in a non-naïve population, where
CHIKV has been endemic for decades, was relatively high with the ratio of subclinical-to-
symptomatic infections notably greater than previous estimates [6,11,12,13,14,17]. The inci-
dence and relative proportion of subclinical infection appeared to be age-dependent. This is
one of the first prospective longitudinal seroepidemiological cohorts undergoing active surveil-
lance with sufficient chikungunya incidence to characterize the proportion of subclinical and
Fig 3. Phylogenetic tree showing five chikungunya viruses (CHIKVs) characterized in the study. The tree was constructed by neighbor-joining
methods (1,000 bootstrap replications) using envelope protein-1 (E1) nucleotide sequences (1,320 bp) of 46 CHIKV strains; the five from the study are
designated in bold. Bootstrap support values are shown for major nodes. Scale bar indicates nucleotide substitutions per site. Genotypes are indicated on
the right. The sequences were named according to virus/country/strain/year of collection or isolation. GenBank accession numbers are shown
in parentheses.
doi:10.1371/journal.pntd.0003764.g003
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symptomatic CHIKV infections in an endemic region. In so doing, our results support CHIKV
PRNT titer as a potential immune correlate of protection from infection.
The proportion of subclinical CHIKV infections in our study was 82.0% compared to 3.8–
27.7% in prior studies [6]. This difference could be due to our study design in which baseline
blood samples were collected in a defined community-based cohort prior to infection followed
by the implementation of a sensitive active surveillance system to detect infection. Thus, we
were able to characterize subclinical versus symptomatic infections more accurately than past
seroprevalence studies which relied on obtaining retrospective histories of symptoms consis-
tent with chikungunya [11,12,13,14]. Of note, since the active surveillance in our study focused
on detecting febrile illness, it is possible that some subjects with “subclinical” infection may
have had no fevers but still had non-febrile symptoms. For example, arthralgia without fever
has been documented in a small percentage of acute CHIKV infections in prior studies [29,30].
Table 2. Incidence of CHIKV infections and seroprevalence of CHIKV PRNT in different age groups.a
Age Subjects,
n
CHIKV PRNT
10, n (% of
age group)b
Symptomatic CHIKV
infection, n [n/100 person-
yrs (95% CI)]
Subclinical CHIKV
infection, n [n/100
person-yrs (95% CI)]
Total CHIKV
infection, n [n/100
person-yrs (95% CI)]
Ratio of subclinical to
symptomatic CHIKV
infection
6 mos
—5 yrs
148 1 (0.7) 5 [3.23 (1.23, 7.08)] 10 [6.46 (3.32, 11.47)] 15 [9.69 (5.66, 15.59)] 2:1
6–15
yrs
184 2 (1.1) 8 [4.23 (1.99, 7.98)] 24 [12.68 (8.33, 18.55)] 32 [16.91 (11.78,
23.56)]
3:1
16–30
yrs
168 34 (20.2) 2 [1.13 (0.23, 3.63)] 20 [11.32 (7.13, 17.14)] 22 [12.45 (8.02,
18.51)]
10:1
31–50
yrs
170 90 (52.9) 3 [1.8 (0.50, 4.81)] 21 [12.63 (8.05, 18.94)] 24 [14.43 (9.49,
21.12)]
7:1
>50
yrs
183 112 (61.2) 1 [0.55 (0.05, 2.59)] 12 [6.66 (3.64, 11.28)] 13 [7.21 (4.04, 11.98)] 12:1
All
ages
853 239 (28.0) 19 [2.19 (1.36, 3.35)] 87 [10.03 (8.09, 12.31)] 106 [12.22 (10.06,
14.72)]
4.6:1
aBased on 853 subjects with both enrollment and 12-month blood collections.
bCHIKV PRNT titer at enrollment using 80% plaque reduction.
CHIKV = chikungunya virus; n = number; CI = conﬁdence interval; PRNT = plaque reduction neutralization test.
doi:10.1371/journal.pntd.0003764.t002
Table 3. Incidence of CHIKV infections among individuals with negative baseline CHIKV PRNT in different age groups.a
Age Subjects with negative
CHIKV PRNTb, n
Symptomatic CHIKV infection, n [n/
100 person-yrs (95% CI)]
Subclinical CHIKV infection, n [n/
100 person-yrs (95% CI)]
Total CHIKV infection, n [n/
100 person-yrs (95% CI)]
6 mos—
5 yrs
147 5 [3.26 (1.23, 7.14)] 10 [6.51 (3.34, 11.55)] 15 [9.77 (5.71, 15.70)]
6–15 yrs 182 8 [4.27 (2.02, 8.06)] 24 [12.82 (8.43, 18.76)] 32 [17.09 (11.91, 23.82)]
16–30
yrs
134 2 [1.42 (0.28, 4.56)] 20 [14.22 (8.96, 21.52)] 22 [15.64 (10.08, 23.25)]
31–50
yrs
80 3 [3.81 (1.06, 10.18)] 21 [26.70 (17.02, 40.04)] 24 [30.51 (20.05, 44.64)]
>50 yrs 71 1 [1.41 (0.13, 6.60)] 12 [16.98 (9.27, 28.75)] 13 [18.39 (10.30, 30.55)]
All ages 614 19 [3.01 (1.87, 4.61)] 87 [13.79 (11.12, 16.92)] 106 [16.80 (13.83, 20.24)]
aBased on 614 subjects with both enrollment and 12-month blood collections who had negative baseline CHIKV PRNT titer.
bCHIKV PRNT titer at enrollment using 80% plaque reduction.
CHIKV = chikungunya virus; n = number; CI = conﬁdence interval; PRNT = plaque reduction neutralization test.
doi:10.1371/journal.pntd.0003764.t003
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Additionally, the genotype or strain of the infecting virus may have been a factor in the high
proportion of subclinical infections. Most studies that have estimated the rate of subclinical in-
fections have been conducted during ECSA genotype outbreaks whereas our study involved
Asian genotype [11,12,13,14]. Interestingly, a large study of chikungunya caused by Asian ge-
notype in 1962 in Bangkok, Thailand, estimated that 25% of Bangkok children had experienced
CHIKV infection based on hemagglutination inhibition (HAI) seroconversion between the
start and end of rainy season while up to 7% of all Bangkok children were estimated to have
sought outpatient medical care for chikungunya, implying the majority of infected children
had subclinical or mild infection [31]. A recent small study of blood donors from the Caribbe-
an island of Saint Martin in 2014 estimated a substantial asymptomatic rate of 40% [32]. Clear-
ly, the relevance of genotype or strain to clinical presentation requires further investigation.
Finally, even the symptomatic CHIKV infections in our study were clinically mild with only
two subjects seeking medical care, and all with complete resolution or minimal symptoms by 3
weeks. The overall high rate of both subclinical and mild infections suggests that the more clin-
ically-apparent chikungunya cases typically reported to public health authorities may represent
Table 4. Clinical presentation of symptomatic CHIKV infections.a
Clinical parameter 6 mos—5 yrs, n (%) 6–15 yrs, n (%) 16–30 yrs, n (%) 31–50 yrs, n (%) >50 yrs, n (%) All ages, n (%)
Fever history 6 (100) 8 (100) 2 (100) 3 (100) 1 (100) 20 (100)
Headache 4 (66.6) 7 (87.5) 2 (100) 1 (33.3) 1 (100) 15 (75)
Rash 5 (83.3) 6 (75) 2 (100) 1 (33.3) 1 (100) 15 (75)
Anorexia 3 (50) 3 (37.5) 2 (100) 3 (100) 1 (100) 12 (60)
Myalgia 2 (33.3) 4 (50) 2 (100) 3 (100) 1 (100) 12 (60)
Arthralgia 2 (33.3) 1 (12.5) 2 (100) 3 (100) 1(100) 9 (45)
Chills 2 (33.3) 2 (25) 2 (100) 2 (66.7) 1 (100) 9 (45)
Conjunctival irritation 2 (33.3) 4 (50) 1 (50) 2 (66.7) 0 (0) 9 (45)
Rhinorrhea/nasal congestion 3 (50) 3 (37.5) 1 (50) 1 (33.3) 0 (0) 8 (40)
Cough 2 (33.3) 2 (25) 2 (100) 1 (33.3) 1 (100) 8 (40)
Abdominal pain 2 (33.3) 3 (37.5) 2 (100) 0 (0) 0 (0) 7 (35)
Sore throat 0 (0) 2 (25) 1 (50) 2 (66.7) 1 (100) 6 (30)
Nausea/vomiting 2 (33.3) 1 (12.5) 0 (0) 2 (66.7) 0 (0) 5 (25)
Hoarseness 1 (16.7) 0 (0) 0 (0) 1 (33.3) 1 (100) 3 (15)
Diarrhea 1 (16.7) 0 (0) 0(0) 0 (0) 0(0) 1 (5)
Sought outpatient medical care 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5)
Hospitalized 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 1 (5)
aBased on 20 symptomatic CHIKV infections and on clinical parameters present at any one of the acute, 2, 5, or 8 day visits.
CHIKV = chikungunya virus; n = number.
doi:10.1371/journal.pntd.0003764.t004
Table 5. Relationship between symptomatic CHIKV infection and baseline enrollment CHIKV PRNT status.a
Baseline CHIKV
PRNT titerb
Symptomatic CHIKV infection
present, n (%)
Symptomatic CHIKV infection
absent, n (%)
Total, n
(%)
% Protection when CHIKV
PRNT 10 (95% CI)
P-
value
<10 19 (3.1) 595 (96.9) 614 (100) 100.0 (46.1, 100.0) 0.003
10 0 (0) 239 (100) 239 (100)
aBased on 853 subjects with both enrollment and 12-month blood collections.
bCHIKV PRNT titer at enrollment using 80% plaque reduction of attenuated vaccine strain 181/clone25.
CHIKV = chikungunya virus; PRNT = plaque reduction neutralization test; n = number; CI = conﬁdence interval.
doi:10.1371/journal.pntd.0003764.t005
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a small fraction of all infections. This has important implications for estimating disease burden,
understanding virus transmission, and assessing blood transfusion risk. The role of subclinical
and mild CHIKV infections in transmitting virus is incompletely understood. However, two
blood donors with asymptomatic infections from the ongoing Caribbean outbreak have been
shown to harbor viable CHIKV [33]. This finding suggests that at least some of the subclinical
infections in our study could potentially participate in virus transmission.
Although CHIKV infections occurred in all age groups, the incidence of total and subclini-
cal infections seemed to vary with age. Considering only subjects with negative CHIKV PRNT
titer at enrollment (among whom all infections occurred), the incidence of total infections was
lowest in subjects 6 months-5 years old. Moreover, the ratio of subclinical-to-symptomatic in-
fection was higher in individuals>15 years old than in those between 6 months and 15 years
old, although the ratio in all ages was quite high. Whether these differences represent typical
age-related patterns or were specific to our study setting is unclear. Many factors could contrib-
ute to these age differences including age-related behavior patterns possibly leading to higher
vector exposure in adolescents and adults, higher mosquito feeding intensity in adults com-
pared to infants and toddlers [34], and more extensive immune histories in adults than chil-
dren not necessarily reflected by PRNT titers that may have contributed to disease prevention
or mitigation. For example, some older adults with negative baseline PRNT titers may, in fact,
have had past infection such that subsequent CHIKV exposure caused a boost in PRNT titer.
This situation would be less likely in children and in naïve populations. Thus, in countries
where CHIKV has not previously circulated, the proportion of mild and subclinical infections
may be lower than in our study. It is also possible that some of the differences among age
groups may have been an artifact of relatively low case numbers in some groups.
The relatively high incidence of CHIKV infection in our study occurred in the Philippines
where sporadic outbreaks have been reported for several decades but with increasing frequency
over the past three years. Cebu province has never reported a chikungunya outbreak and has
documented very few individual cases including during the current study period (communica-
tion, Dr. Vito G. Roque, Philippine DOH). The nonspecific nature of symptoms and the high
rate of subclinical and mild infections may partly account for this lack of reported cases. Addi-
tional prospective cohort studies with active fever surveillance may be highly informative even
in regions with few reported cases.
Our study allowed for the evaluation of potential immune correlates of protection from
CHIKV infection in humans. Previous animal studies have demonstrated that CHIKV neutral-
izing antibodies are associated with protection in mice [35,36] and non-human primates
[37,38]. Human studies of CHIKV antibodies following infection have suggested neutralizing
antibodies correlate with viral clearance and long-term clinical protection [39,40]. Our results
demonstrated that a positive baseline CHIKV PRNT titer was associated with protection from
symptomatic CHIKV infection in humans. This is one of the first human field studies to find
such an association and will contribute to the increasing body of evidence supporting CHIKV
neutralizing antibodies as an immune correlate of protection from infection.
Although not included among those with symptomatic and subclinical CHIKV infections,
four subjects with an enrollment PRNT titer10 had a 4 to 8-fold rise in PRNT titer at 12
months (increasing from 10 to 42, 59 to 286, 83 to 555, and 162 to 799, respectively), and one
subject had a8-fold rise (from 95 to 959). It is unclear whether these results were due to assay
variability or to immunological boosting after virus exposure. The8-fold rise was probably
due to the latter. In any event, the small number of such cases and the relatively small increase
in titer suggest that most subjects with a positive PRNT titer probably had a certain degree of
sterile immunity.
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Several limitations of the study should be noted. First, the results are from a single study
year in a limited study population and geographic area potentially limiting the generalizability
of the results. Second, the CHIKV strain identified in this study was Asian genotype which
could behave differently from other CHIKV genotypes such as ECSA. Nevertheless, the find-
ings are directly applicable to closely-related Asian strains such as those detected recently from
the Caribbean outbreak. Third, although serological cross-reactivity with other alphaviruses is
theoretically possible, the relatively large number of CHIKV PCR-positive samples in our
study combined with the extremely low CHIKV seroprevalence in subjects15 years old sug-
gesting minimal CHIKV activity over the past 15 years, and the lack of any confirmed non-
CHIKV human alphavirus infections in the Philippines make it unlikely that other alpha-
viruses were responsible for the seropositivity seen in our study. Fourth, although active sur-
veillance was used to identify febrile episodes, some illnesses may have gone undetected
leading to an overestimation of subclinical infections. Finally, the relatively low number of
symptomatic infections led to relatively large confidence intervals. Therefore, a larger number
of CHIKV infections in future studies may be necessary to confirm our findings.
In summary, subclinical and mild CHIKV infections may account for a much larger propor-
tion of total infections than previously reported, with substantial underreporting to public
health systems. This has implications for accurate assessments of chikungunya disease burden,
virus transmission, and blood transfusion risk. The finding that a positive CHIKV PRNT titer
was associated with protection from infection will contribute to ongoing vaccine development
efforts. Additional prospective longitudinal cohort studies should be done to validate our find-
ings in other regions with known chikungunya activity.
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